Evidence map›Paper›PMID 27008703›Full record

ArticleOncotarget2016

MiR-128-2 inhibits common lymphoid progenitors from developing into progenitor B cells.

Yi Yang, Jie Xu, Huo Chen, Xia Fei, YuXu Tang, Yunqiu Yan, Huimin Zhang, Jinping Zhang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yi YangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Jie XuInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Huo ChenInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Xia FeiInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
YuXu TangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Yunqiu YanInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Huimin ZhangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Jinping ZhangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A considerable number of studies revealed that B cell development is finely regulated by transcription factors (TFs). Recent studies suggested that TFs are coordinated with microRNAs to control the development of B cells in numerous checkpoints. In the present study, we first found that miR-128-2 was differentially expressed in various immune organs and immunocytes. B cell development was inhibited in miR-128-2-overexpressed chimera and transgenic (TG) mice in bone marrow with decreased preproB, preB, proB, immature B, and recirculating B cells, as well as increased common lymphoid progenitors (CLPs). Further experiments showed that the apoptosis of CLP decreased, but proliferation was not altered in miR-128-2-overexpressed mice. Extensive studies suggested that the inhibition of apoptosis of CLP may be caused by miR-128-2 targeting A2B and MALT1, thereby increasing the phosphorylation of ERK and P38 MAPK. Such findings have prompted future investigations on the function of miR-128-2 in lymph genesis.

Indexed as

AnimalsApoptosisBone Marrow CellsCaspasesCell DifferentiationExtracellular Signal-Regulated MAP KinasesLymphoid Progenitor CellsMiceMice, Inbred C57BLMice, TransgenicMicroRNAsMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNeoplasm Proteinsp38 Mitogen-Activated Protein KinasesPhosphorylationPrecursor Cells, B-LymphoidCaspasesExtracellular Signal-Regulated MAP KinasesMalt1 protein, mouseMicroRNAsMirn128 microRNA, mouseMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNeoplasm Proteinsp38 Mitogen-Activated Protein KinasesapoptosisB cell developmentCLPImmune responseImmunityImmunology and Microbiology SectionmiR-128-2

Identifiers

PMID27008703
PMCPMC4951230
OpenAlexW2304372001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.